When PS is appropriate
Example 9 — Compound A + Enzyme B — combination creates value
Annex II Ch.II · Example 9 · ¶42–45 · AB Inc
OECD Guidelines 2022At a glance
ACo and BCo each developed unique components — Compound A and Enzyme B — for their own purposes. Neither has significant value on its own. Engineers from both discover that combined they create a highly valuable drug. ACo licenses Compound A to BCo, which combines and markets. Method?
The parties
ACo (Country A)
Worldwide patent on Compound A · originally unrelated purposeright to use Compound A
BCo (Country B)
Worldwide patent on Enzyme B · combines and markets the drugWhat happens
- ACo and BCo each independently develop their own component for different intended purposes.
- Neither component has significant value on its own.
- Engineers from both companies, working together, discover that combining Compound A with Enzyme B produces a unique and effective drug.
- ACo grants BCo the right to use Compound A; BCo combines the components and markets the resulting drug.
Analysis
Each component alone is nearly worthless. They become unique and valuable only when combined.
Which method best prices the right to use Compound A?
OECD analysis · Profit split most appropriate
Per Annex II Ch.II · Example 9 (¶45), high integration and inter-dependency mean each contribution is unique and valuable in combination — so profit split is the most appropriate method. A CUP fails because the value emerges only from the specific combination. Cost-plus on ACo strips out the unique value of Compound A in this combination — which, alone, was practically worthless.
Key takeaway
Uniqueness can emerge from combination, not just from a single contribution standing alone. Two items neither of which has standalone value can still be unique and valuable together.
Related: ¶2.130 (unique and valuable contributions) · ¶2.131 (uniqueness in combination)